PRELIMINARY PROGRAM

Monday, January 15, 2024

09.00 am Welcome and Introduction

SESSION I: CAR-T, update clinical trials and RWE

Chairman: P. Corradini

09.15 am	HG-BCL	S.J. Schuster
09.45 am	Follicular Lymphoma	C.A. Jacobson
10.15 am	Mantle Cell Lymphoma	M. Wang

SESSION II: Hodgkin's lymphoma

Chairman: S.M. Ansell, P.L. Zinzani

10.45 am	Frontline advanced stage	J. Friedberg
11.00 am	1st relapse	C.H. Moskowitz
11.15 am	New agents in R/R patients	A.S. La Casce
11.30 am	Treatment strategies in elderly patients	A. Sureda
11.45 am	Primary mediastinal lymphoma	K. Dunleavy
12.00 pm	Grey zone lymphoma	S.M. Ansell
12.15 pm	CAR-T	F. Locatelli

Lectures on PROTAC Therapies

Chairman: B. Cheson

12.50 pm	NX-2127	A.V. Danilov
01.10 pm	BGB-16673	C.Y. Cheah

01.30 pm Lunch

SESSION III: Acute leukemias

Chairmen: A. Curti, A. Venditti

02.30 pm	Immunotherapy in AML: targeting immunosuppressive microenvironment	M. Ciciariello
02.45 pm	Targeting CD123 in AML and BPDCN	R. Lemoli
03.00 pm	Anti-CD47 MoAbs in AML and MDS	D.A. Sallman
03.15 pm	Immune checkpoint inhibitors in AML and MDS	G. Manero
03.30 pm	T-cell engagers in AML and ALL	M. Subklewe
03.45 pm	IDH inhibitor: ivo, ena and beyond	P. Montesinos
04.15 pm	*Coffee break*	
04.30 pm	BCL2 inhibitors: not only venetoclax	A.H. Wei
04.45 pm	Novel FLT3 inhibitors	M.J. Levis
05.00 pm	Subcutaneous blinatumomab in adult ALL	A. Rambaldi
05.15 pm	Menin-inhibitors	C. Papayannidis
05.30 pm	BMF-219 and BFM-500	*TBD*
05.45 pm	Targeting the BCL2/BCLx pathway in T-ALL	E. Jabbour
06.00 pm	CAR-T cells for adult ALL and AML	M. Ruella

Tuesday, January 16, 2024

SESSION IV: Classical Ph1-neg myeloproliferative neoplasms

Chairmen: F. Palandri, A.M. Vannucchi

08.30 am	Cytoreduction in low-risk PV: when, and which drug?	H. Gisslinger
08.45 am	Hydroxyurea, interferons, ruxolitinib or clinical trials: what sequence in polycythemia vera?	F. Palandri
09.00 am	The future of 1st line therapy in myelofibrosis	A. Kuykendall
09.15 am	Second-line therapy of myelofibrosis	H.K. Al-Ali
09.30 am	What is disease modification in myelofibrosis	A. Reiter
09.45 am	MPNs in accelerated/blast phase	P. Guglielmelli

SESSION V: Non-Hodgkin's lymphoma (I)

Chairman: C. Carlo-Stella, M. Ladetto

10.00 am	Tafasitamab	J.A. Duell
10.15 am	Epcoritamab	C. Thieblemont
10.30 am	Glofitamab	M. Dickinson
10.45 am	Mosunetuzumab	E.L. Budde
11.00 am	Odronextamab	W.S. Kim
11.15 am	TNB-486	J.Z. Hou

11.30 am	Polatuzumab vedotin	B.D. Cheson
11.45 am	Loncastuximab tesirine	M. Hamadani
12.00 pm	Tazemetostat	C.L. Batlevi
12.45 pm	Lunch	

SESSION VI: Non-Hodgkin's lymphoma (II)

Chairmen: M. Martelli, M. Spina

02.00 pm	Zilovertamab	M. Wang
02.15 pm	Linperlisib	S.P. Iyer
02.30 pm	Pirtobrutinib	M. Wang
02.45 pm	Zanubrutinib	P.L. Zinzani
03.00 pm	Golidocitinib	W.S. Kim
03.15 pm	Valemetostat	S. Horwitz
03.30 pm	Iberdomide	C. Thieblemont
03.45 pm	Golcadomide	J.M. Michot
04.00 pm	CDK9 inhibitors	J. Zain

Session VII: Non-Hodgkin's lymphoma – The next steps of CAR-T

Chairman: S.J. Schuster

04.30 pm	New generations of CAR-T	S.J. Schuster
04.45 pm	Allo CAR-T	S.S. Neelapu
05.00 pm	NK CAR-T	K.Rezvani
05.15 pm	Gamma delta CART19	S.S. Neelapu

SESSION VIII: Chronic myeloid leukemia

Chairman: M. Breccia, F. Castagnetti

05.45 pm	Status of the art of treatment	M. Breccia
06.00 pm	Asciminib	D. Rea
06.15 pm	Ponatinib	F. Castagnetti
06.30 pm	Second generation TKIs	T.H. Bruemmendorf
06.45 pm	New agents	M. Bonifacio
07.00 pm	Treatment free remission	S. Saussele

Wednesday, January 17, 2024

Lectures

Chairman: N. Vianelli

08.30 am	New agents in the treatment of immune thrombocytopenia	D. Provan
09.00 am	Improving outcomes of EBV+ PTLD with T-cell immunotherapy	D. Dierickx

SESSION IX: Chronic Lymphocitic Leukemia

Chairmen: F. Mauro, A. Tedeschi

09.30 am	Ibrutinib	S.M. O'Brien
09.45 am	Venetoclax	K. Fischer
10.00 am	Acalabrutinib	J.C. Byrd
10.15 am	Zanubrutinib	J. Brown
10.30 am	Pirtobrutinib	W. Jurczak
10.45 am	Nemtabrutinib	J.C. Byrd
11.00 am	BGB-11417	C.Y. Cheah
11.15 am	CAR-T	T. Siddiqi

SESSION X: Multiple myeloma

Chairmen: M. Cavo, P. Moreau

11.45 am	2nd generation anti-BCMA and -GPRC5D autologous CAR-T	N. Munshi
12.00 pm	Novel CAR-T manufacturing and allogeneic CAR-T	S. Mailankody
12.15 pm	Antibody drug conjugates	S. Trudel
12.30 pm	Bispecific antibodies	P. Moreau
12.45 pm	Resistance mechanisms	P. Neri
01.00 pm	T cell directing therapies sequencing	S. Kumar

01.30 pm **Arrivederci**